Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2018
Event: Entry into a Material Definitive Agreement (Second Amended and Restated License Agreement) with Incept LLC, an intellectual property holding company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The document focuses on the terms of a license agreement. Key financial terms include:
- Royalties (Ophthalmic Field): Low single-digit percentage of net sales for products covered by Original IP (excluding Shape-Changing IP).
- Royalties (Additional Field): Mid-single-digit percentage of net sales for products covered by Original IP (excluding Shape-Changing IP) in fields such as acute post-surgical pain and ear, nose, and throat diseases.
- Royalties (Drug Delivery): Low single-digit percentage of net sales for products covered by Incept IP or Joint IP.
- Sublicense Payments: Incept may require payments equal to a mid-teen percentage of upfront payments received by the Company from sublicensees in the Additional Field of Use.
Material Changes Versus Prior Period
The Second Amended Agreement modifies the Prior Agreement (dated January 27, 2012) in the following ways:
- Expanded Scope: The license now covers the "Additional Field of Use" (acute post-surgical pain; ear, nose, and throat diseases) and expands rights for "Shape-Changing IP" to all fields except specific nerve-related tissues.
- IP Ownership: The Company will solely own intellectual property conceived solely by Company individuals after the Effective Date ("Ocular IP"). Incept retains ownership of Original IP, Incept IP, and Joint IP.
- Patent Control: Incept retains control of Original IP prosecution. The Company controls prosecution for Incept IP and Joint IP. A separate agreement is planned for the Company to assume control of Shape-Changing IP prosecution.
Guidance, Outlook, and Risks
Management Commentary: The Company expects the agreement to facilitate the assessment and potential use of its hydrogel platform technology for drug delivery beyond the eye and outside ophthalmology.
Risks and Contingencies:
- Related Party Transaction: Amarpreet Sawhney, the Company's Chairman and former CEO, is a general partner with a 50% ownership stake in Incept.
- Forward-Looking Statements: Risks include timing and costs of commercialization, clinical trial outcomes, regulatory approvals, sufficiency of cash resources, and the need for additional financing.
- Legal Costs: The Company is responsible for all costs incurred in prosecuting infringement actions it brings.
Important Facts for Investor Verification
- Verify the specific definitions of "Original IP," "Incept IP," and "Joint IP" in the attached Exhibit 10.1 to understand the scope of royalty obligations.
- Confirm the Company's current cash runway and financing needs, as the filing notes the sufficiency of cash resources as a risk factor.
- Review the status of the separate agreement regarding the Company's assumption of control over Shape-Changing IP prosecution.
- Assess the potential financial impact of the mid-teen percentage payments on future sublicense deals in the Additional Field of Use.